Liquidity Mapping Around (UTMD) Price Events
The article provides a detailed analysis of Utah Medical Products Inc. (UTMD) based on AI-generated signals, highlighting a strong near-term sentiment but neutral mid and long-term outlook. It identifies key resistance and support levels, presenting specific institutional trading strategies for various risk profiles, including long, breakout, and short setups. The analysis emphasizes a high risk-reward short setup with significant downside target against minimal risk.
Utah Medical Products' (NASDAQ:UTMD) Dividend Will Be $0.31
Utah Medical Products (NASDAQ:UTMD) is set to distribute a dividend of $0.31 per share on April 3rd, resulting in a 2.0% dividend yield. The company's dividends are well-covered by both cash flow and earnings, with projected earnings per share growth of 3.7% over the next year. Utah Medical Products boasts a stable dividend payment history over the last decade, making it an attractive option for income investors, despite limited dividend growth prospects.
Utah Medical's Q4 earnings hurt by OEM decline, fall y/y
Utah Medical Products (NASDAQ:UTMD) reported a decline in its Q4 earnings year-over-year, primarily attributed to a significant drop in its OEM sales. Excluding the OEM segment, the company's Q4 revenue saw a modest increase of 0.6% compared to the previous year. Despite the overall earnings dip, Utah Medical Products continues to operate debt-free.
Utah Medical Products, Inc. (NASDAQ:UTMD) Announces Quarterly Dividend of $0.31
Utah Medical Products, Inc. (NASDAQ:UTMD) has declared a quarterly dividend of $0.31 per share, payable on April 3rd to shareholders of record by March 17th. This dividend represents an annualized yield of 2.0%. The company has consistently increased its dividend for the past three consecutive years, although its average dividend growth over this period is reported as flat at 0.0%.
Why (UTMD) Price Action Is Critical for Tactical Trading
This article analyzes Utah Medical Products Inc. (UTMD) stock, highlighting a strong near-term sentiment with a neutral mid and long-term outlook. It identifies a significant risk-reward short setup and outlines three distinct AI-generated trading strategies: Position Trading, Momentum Breakout, and Risk Hedging, tailored for different risk profiles. The analysis emphasizes the importance of price action for tactical trading and provides support and resistance levels across various time horizons.
Utah Medical Products raises quarterly dividend by 1.6% to $0.31
Utah Medical Products (NASDAQ:UTMD) announced a 1.6% increase in its quarterly cash dividend to $0.31 per share, payable on April 3, 2026. The company, which specializes in healthcare products for women and babies, boasts a 2.0% dividend yield and has maintained payments for 22 consecutive years. This news follows the recent appointment of Kevin C. Timken to its Board of Directors, signaling strategic adjustments and efforts to enhance shareholder value.
Utah Medical Products raises quarterly dividend by 1.6% to $0.31
Utah Medical Products (NASDAQ:UTMD) has announced a 1.6% increase in its quarterly cash dividend to $0.31 per share, payable on April 3, 2026. The company, which specializes in healthcare products for women and babies, offers a 2.0% dividend yield and has maintained payments for 22 consecutive years. This news follows the appointment of Kevin C. Timken to its Board of Directors, reinforcing strategic adjustments aimed at enhancing governance and shareholder value.
Utah Medical Products Keeps Quarterly Dividend at $0.31 per Share, Payable April 3 to Holders of Record March 17
Utah Medical Products (UTMD) has announced that it will maintain its quarterly dividend at $0.31 per share. The dividend is scheduled to be paid on April 3 to shareholders who are on record as of March 17. The company specializes in medical devices for critical care and women's health.
Utah Medical's Q4 Earnings Hurt by OEM Decline, Fall Y/Y
Utah Medical Products (UTMD) reported a decline in Q4 2025 earnings and revenues, with EPS dropping 6.3% and revenues falling 1.2% year-over-year. The decrease was primarily driven by softness in U.S. sales of non-Filshie medical devices and a significant 31.5% drop in OEM sales, partially offset by an increase in OUS sales due to favorable foreign exchange rates. Despite the revenue decline, the company maintained a strong gross profit margin and ended the year with $85.8 million in cash and no debt, continuing share repurchases and dividends.
Utah Medical's Q4 Earnings Hurt by OEM Decline, Fall Y/Y
Utah Medical Products, Inc. (UTMD) reported a decline in Q4 2025 earnings and revenues, with EPS falling 6.3% and revenues down 1.2% year-over-year. The decrease was primarily attributed to soft U.S. sales of non-Filshie devices and a significant 31.5% drop in OEM sales, despite growth in U.S. Filshie device sales and a modest benefit from favorable foreign exchange rates in OUS sales. The company's full-year 2025 sales also decreased by 5.8%, and management expects continued challenges but plans to offset losses with new products and organic growth.
Utah Medical Products raises quarterly dividend by 1.6% to $0.31
Utah Medical Products (NASDAQ:UTMD) has announced a 1.6% increase in its quarterly cash dividend to $0.31 per share. The company, which specializes in healthcare products for women and babies, will pay the dividend on April 3, 2026, to shareholders of record on March 17, 2026. UTMD boasts a "GREAT" financial health score, a 2.0% dividend yield, and a 22-year history of consecutive dividend payments.
Dividend rises 1.6% at Utah Medical, now $0.31 a share
Utah Medical Products (Nasdaq: UTMD) announced a quarterly cash dividend of $0.31 per share, payable on April 3, 2026, to shareholders of record as of March 17, 2026. This dividend represents a 1.6% increase compared to the same quarter last year. The company specializes in developing and marketing medical devices for women and babies, distributing its products in over 100 countries.
Utah Medical's Q4 Earnings Hurt by OEM Decline, Fall Y/Y
Utah Medical Products (UTMD) recently reported Q4 2025 earnings per share of 80.2 cents, a 6.3% decrease year-over-year, and revenues of $9 million, down 1.2% from the prior year. The decline was primarily attributed to a significant drop in OEM sales and weak domestic U.S. sales of non-Filshie devices, despite growth in U.S. Filshie sales and a slight boost from favorable foreign exchange rates in international markets. The company managed to maintain a strong gross profit margin through cost containment efforts, but overall profitability was impacted by higher operating expenses and ongoing cost pressures.
Utah Medical: Fourth Quarter Earnings Overview
Utah Medical Products Inc. announced its financial results for the fourth quarter, reporting a net profit of $2.6 million and earnings of $0.80 per share, with revenue reaching $9 million. For the full year, the company achieved a total profit of $11.3 million, or $3.48 per share, on annual revenue of $38.5 million. The information provided is based solely on the author's opinion and is not investment advice.
Utah Medical Products (UTMD) Margin Decline Challenges Steady Compounder Narrative
Utah Medical Products (UTMD) closed FY 2025 with Q4 revenue of US$9.0 million and basic EPS of US$0.80, showing a relatively tight range in earnings and sales over recent quarters. The company's net profit margin decreased from 34.6% to 30.1% over the last 12 months, and trailing EPS has softened after a period of modest five-year growth. Despite this, UTMD remains profitable and trades at a P/E of 16.8x, significantly below industry averages, suggesting a potential undervaluation based on DCF estimates.
Utah Medical: Q4 Earnings Snapshot
Utah Medical Products Inc. (UTMD) reported net income of $2.6 million, or 80 cents per share, in its fourth quarter, with revenue reaching $9 million. For the full year, the company's profit was $11.3 million ($3.48 per share) on $38.5 million in revenue. This financial snapshot was generated by Automated Insights using data from Zacks Investment Research.
Utah Medical: Fourth Quarter Earnings Overview
Utah Medical Products Inc. announced its financial results for the fourth quarter, reporting a net profit of $2.6 million and earnings of $0.80 per share. The company generated $9 million in revenue for the quarter. For the full year, Utah Medical Products achieved a total profit of $11.3 million, or $3.48 per share, with annual revenue reaching $38.5 million.
Utah Medical: Q4 Earnings Snapshot
Utah Medical Products Inc. (UTMD) reported a net income of $2.6 million, or 80 cents per share, in its fourth quarter. The company, a medical device maker, also posted revenues of $9 million for the period. For the full year, Utah Medical achieved a profit of $11.3 million, or $3.48 per share, on revenues of $38.5 million.
Utah Medical: Q4 Earnings Snapshot
Utah Medical Products Inc. reported net income of $2.6 million for its fourth quarter, translating to 80 cents per share, with revenues totaling $9 million. For the entire year, the medical device maker achieved a profit of $11.3 million, or $3.48 per share, on revenues of $38.5 million. This financial snapshot was generated by Automated Insights using data from Zacks Investment Research.
Avoiding Lag: Real-Time Signals in (UTMD) Movement
The article provides real-time signal analysis for Utah Medical Products Inc. (NASDAQ: UTMD), indicating strong near- and mid-term sentiment that could extend long-term. It highlights an exceptional 27.4:1 risk-reward setup, targeting an 8.0% gain versus a 0.3% risk. Three distinct AI-generated trading strategies are presented for different risk profiles, along with multi-timeframe signal analysis and key support/resistance levels.
United States Smoke Evacuation System Market Size, Share & Future Opportunities to 2030
The United States Smoke Evacuation System Market is projected to grow at a CAGR of 6.5% during the forecasting period (2023-2030). Key players like Medtronic, CONMED, and CooperSurgical are driving market advancements through innovative solutions and enhanced safety features. The market's growth is attributed to strict surgical safety regulations in North America, with significant developments including advanced filtration systems, portable units, and improved ergonomic designs being introduced.
Discipline and Rules-Based Execution in UTMD Response
Stock Traders Daily provided an analysis for Utah Medical Products Inc. (NASDAQ: UTMD), highlighting a neutral sentiment across all horizons and a mid-channel oscillation pattern. The analysis includes three distinct institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis and an exceptional risk-reward short setup.
Utah Medical Products (NASDAQ:UTMD) Hasn't Managed To Accelerate Its Returns
Utah Medical Products (UTMD) has shown stable but not accelerating returns on capital employed over the last five years, indicating it may be past its growth phase. The company's ROCE stands at 11%, aligning with industry averages. Consequently, the stock has seen a 26% decline in the last five years, suggesting market skepticism about future growth.
Utah Medical Products (NASDAQ:UTMD) Stock Crosses Below Two Hundred Day Moving Average - Here's Why
Utah Medical Products (NASDAQ:UTMD) stock recently fell below its 200-day moving average, trading at $56.75 on Friday with a volume of 14,856 shares. Analysts, including Weiss Ratings, have reiterated a "Sell" rating for the company, reflecting cautious sentiment. Despite this, the company reported strong fundamentals with a market capitalization of $181.6 million, a P/E ratio of 16.03, and a quarterly EPS of $0.82 on $9.81 million in revenue, in addition to increasing its quarterly dividend to $0.31 per share.
(UTMD) Movement as an Input in Quant Signal Sets
This article provides an in-depth analysis of Utah Medical Products Inc. (NASDAQ: UTMD) using quantitative signals. It highlights conflicting sentiment across different time horizons, suggesting choppy market conditions, and offers specific institutional trading strategies including position trading, momentum breakout, and risk hedging. The analysis also details multi-timeframe signal analysis with support and resistance levels.
Utah Medical Products (NASDAQ:UTMD) Stock Crosses Below 200 Day Moving Average - Here's What Happened
Utah Medical Products (NASDAQ:UTMD) saw its share price fall below its 200-day moving average, trading as low as $57.12 and closing at $57.39, below its 200-day MA of $58.26. Analysts, including Weiss Ratings, have reissued a "sell" rating for the stock. Despite the stock performance, the company declared a quarterly dividend of $0.31 per share.
(UTMD) Volatility Zones as Tactical Triggers
This article analyzes Utah Medical Products Inc. (NASDAQ: UTMD) using AI models, identifying a mid-channel oscillation pattern and a strong risk-reward setup targeting an 8.5% gain. It details three trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis, emphasizing prevailing positive sentiment. The analysis suggests that if near- and mid-term strong sentiment holds, it could extend to the long term, offering specific entry, target, and stop-loss zones for tactical trading.
Brandes Investment Partners LP Acquires 29,073 Shares of Utah Medical Products, Inc. $UTMD
Brandes Investment Partners LP has increased its stake in Utah Medical Products, Inc. by 12.0% in Q2, purchasing 29,073 additional shares and now owning 271,322 shares valued at approximately $15.44 million. The company recently declared a quarterly dividend of $0.31 per share which will be paid on January 5th. Despite the increased institutional ownership, analyst sentiment for Utah Medical Products remains negative with an average rating of "Sell."
Price-Driven Insight from (UTMD) for Rule-Based Strategy
This article provides a price-driven insight into Utah Medical Products Inc. (NASDAQ: UTMD) for rule-based strategies. It highlights divergent sentiment readings, a mid-channel oscillation pattern, and an exceptional risk-reward short setup. The AI models have generated three distinct trading strategies for various risk profiles and holding periods, along with multi-timeframe signal analysis.
Shareholders in Utah Medical Products (NASDAQ:UTMD) are in the red if they invested three years ago
Shareholders of Utah Medical Products (NASDAQ:UTMD) who invested three years ago have seen a 38% decrease in share price, underperforming the broader market. Despite a slower 6.3% annual reduction in EPS, the market's previous confidence might have been overstated. The total shareholder return (TSR) including dividends was slightly better at -34%.
UTMD's Q3 Earnings Dip Y/Y on Trade Disruptions, Margins Squeeze
Utah Medical Products, Inc. (UTMD) experienced a decline in its third-quarter 2025 earnings per share and revenue, attributed to trade disruptions, unexpected order cancellations, and increased tariffs. The company's gross and operating margins contracted, leading to reduced profitability, despite ongoing cost control efforts. Management has revised its full-year 2025 revenue outlook downwards, reflecting the challenging operating environment.
Utah Medical Products (NASDAQ:UTMD) Is Increasing Its Dividend To $0.31
Utah Medical Products (NASDAQ:UTMD) has announced an increase in its dividend to $0.31 per share, representing a 1.6% rise from the previous year. This brings the annual payment to 2.1% of the stock price, exceeding most industry peers. The company's dividends are well-covered by earnings and cash flow, contributing to its solid dividend track record and potential as an income stock.
Utah Medical Products, Inc. Reports Financial Performance for Q3 and 9M 2025
Utah Medical Products, Inc. (UTMD) has released its financial results for Q3 and the first nine months of 2025, reporting decreased net sales and income due to global trade uncertainties and distributor cancellations. The company's Q3 net sales fell by 1.9% to $9.8 million, and net income decreased by 26.2%. For the nine-month period, net sales were down 7.2% to $29.5 million, with net income seeing a 20.5% reduction.
Utah Medical (NASDAQ: UTMD) appoints Kevin C. Timken, declares $0.31 dividend
Utah Medical Products (UTMD) has appointed Kevin C. Timken to its Board of Directors and approved a quarterly cash dividend of $0.31 per share, representing a 1.6% increase. The dividend is payable on January 5, 2026, to shareholders of record on December 16, 2025. Mr. Timken brings over 20 years of experience as the company’s outside legal counsel.
Utah Medical Products appoints new board member, raises dividend
Utah Medical Products, Inc. (NASDAQ:UTMD) has appointed Kevin C. Timken to its Board of Directors and announced a quarterly cash dividend of $0.31 per share, representing a 1.6% increase. Timken previously served as the company’s outside legal counsel for over twenty years. The company, which has a market cap of $187.41 million, develops specialty medical devices and has maintained dividend payments for 22 consecutive years.
Utah Medical Products appoints new board member, raises dividend
Utah Medical Products, Inc. (NASDAQ:UTMD) has appointed Kevin C. Timken to its Board of Directors and announced a quarterly cash dividend increase of 1.6% to $0.31 per share. The company, a medical device manufacturer, has maintained dividend payments for 22 consecutive years and exhibits strong financials with a high current ratio and more cash than debt. InvestingPro data suggests UTMD is undervalued with a P/E ratio of 16.82 and a 10% return on equity.
FMR LLC Reduces Stake in Utah Medical Products Inc
FMR LLC, also known as Fidelity, reduced its stake in Utah Medical Products Inc (UTMD) by selling 145,639 shares at $67.91 each on November 8, 2024. Despite this reduction, FMR LLC retains a significant holding of 268,823 shares, representing 7.73% of its portfolio. This strategic adjustment comes as UTMD, specializing in medical devices, is considered modestly undervalued with a GF Value of $84.14, and its stock has seen a year-to-date decline but a substantial increase since its IPO.
Utah Medical Products, Inc. Reports Financial Performance for First Quarter 2022
Utah Medical Products, Inc. (Nasdaq: UTMD) announced strong financial results for the first quarter of 2022, with revenues up 12.4%, net income up 16.9%, and EPS up 16.6% compared to the same period in 2021. The growth was driven by increased domestic sales and, despite foreign currency headwinds, constant currency OUS sales also showed improvement. The company maintained a strong balance sheet with increased cash and investments, and management expects performance to be consistent with achieving its 2022 financial objectives.
Postpartum Hemorrhage (PPH) Devices Market Top-Companies, Future-Growth, Regional Analysis, Business-Opportunities 2027
The Postpartum Hemorrhage (PPH) Devices Market was valued at $637 million in 2015 and is projected to reach $906 million by 2022, growing at a CAGR of 5.2%. Key drivers include increasing pregnancy complications and technological advancements, though lack of trained professionals in developing countries may hinder growth. The report also addresses the impact of COVID-19 on the market and provides segmentation by product and region.
